Daily Stock Analysis, CLRB, Cellectar Biosciences Inc, priceseries

Cellectar Biosciences Inc. Daily Stock Analysis
Stock Information
Open
2.29
Close
2.33
High
2.39
Low
2.21
Previous Close
2.32
Daily Price Gain
0.01
YTD High
3.75
YTD High Date
Mar 19, 2019
YTD Low
1.48
YTD Low Date
Jan 2, 2019
YTD Price Change
0.75
YTD Gain
47.47%
52 Week High
4.28
52 Week High Date
Oct 2, 2018
52 Week Low
1.22
52 Week Low Date
Dec 24, 2018
52 Week Price Change
0.03
52 Week Gain
1.30%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jan 23. 2017
13.80
Feb 23. 2017
22.01
22 Trading Days
59.51%
Link
LONG
Sep 12. 2017
16.20
Sep 20. 2017
17.28
6 Trading Days
6.68%
Link
LONG
Dec 20. 2017
12.30
Jan 4. 2018
13.01
9 Trading Days
5.81%
Link
LONG
Jul 13. 2018
7.40
Jul 17. 2018
10.08
2 Trading Days
36.22%
Link
LONG
Sep 19. 2018
2.42
Oct 3. 2018
3.06
10 Trading Days
26.40%
Link
LONG
Mar 14. 2019
2.16
Mar 21. 2019
2.33
5 Trading Days
7.99%
Link
Company Information
Stock Symbol
CLRB
Exchange
NasdaqCM
Company URL
http://www.cellectar.com
Company Phone
(608) 441-8120
CEO
James V. Caruso
Headquarters
Wisconsin
Business Address
3301 AGRICULTURE DRIVE, MADISON, WI 53716
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001279704
About

Cellectar BioSciences, Inc. operates as a biopharmaceutical company. It engages developing phospholipid drug conjugates designed to provide cancer targeted delivery of oncologic payloads to cancer stem cells. The company was founded on April 11, 2011 and is headquartered in Madison, WI.

Description

Cellectar Biosciences, Inc., a clinical stage biopharmaceutical company, engages in the development of targeted phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. It offers CLR 131, a PDC radiotherapeutic product candidate and is currently being evaluated in a Phase I study for the treatment of relapse or refractory multiple myeloma; CLR 125, a cancer-targeting radiotherapeutic is under pre-clinical investigation for the treatment of micrometastatic disease ; CLR 124, a cancer-targeting positron emission tomography (PET) imaging PDC for the selective detection of tumors and metastases in a broad range of cancers; and CLR 1502, a cancer-targeting NIR-fluorophore optical imaging PDC for intraoperative tumor and tumor margin illumination. The company was formerly known as Novelos Therapeutics, Inc. and changed its name to Cellectar Biosciences, Inc. in February 2014. Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Madison, Wisconsin.